Heartflow, Inc. (HTFL) — SEC Filings
Heartflow, Inc. (HTFL) — 10 SEC filings. Latest: ARS (Apr 29, 2026). Includes 3 8-K, 2 10-Q, 2 S-1/A.
View Heartflow, Inc. on SEC EDGAR
Overview
Heartflow, Inc. (HTFL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 29, 2026: Heartflow, Inc. filed an Annual Report to Security Holders (ARS) on April 29, 2026, for the period ending December 31, 2025. The company, located at 135 Main Street, Suite 1000, San Francisco, CA 94105, is involved in the Surgical & Medical Instruments & Apparatus industry.
Sentiment Summary
Across 10 filings, the sentiment breakdown is: 7 neutral, 3 mixed. The dominant filing sentiment for Heartflow, Inc. is neutral.
Filing Type Overview
Heartflow, Inc. (HTFL) has filed 1 ARS, 1 DEFA14A, 2 10-Q, 3 8-K, 2 S-1/A, 1 S-1 with the SEC between Jul 2025 to Apr 2026.
Filings by Year
Recent SEC Filings (10)
| Date | Form | Description | Risk |
|---|---|---|---|
| Apr 29, 2026 | ARS | Heartflow, Inc. Files Annual Report for 2025 | low |
| Apr 29, 2026 | DEFA14A | Heartflow Inc. Files Definitive Proxy Statement | low |
| Nov 12, 2025 | 10-Q | Heartflow Revenue Soars 39.7%, IPO Boosts Cash Amid Widening Losses | high |
| Sep 19, 2025 | 10-Q | Heartflow Revenue Soars 40%, Net Loss Narrows on Convertible Note Boost | medium |
| Sep 10, 2025 | 8-K | Heartflow, Inc. Files 8-K on Financials and Reg FD | low |
| Aug 25, 2025 | 8-K | Heartflow, Inc. Terminates Material Definitive Agreement | medium |
| Aug 11, 2025 | 8-K | Heartflow, Inc. Files 8-K with Corporate Updates | low |
| Aug 6, 2025 | S-1/A | Heartflow Files S-1/A Amendment 2, Nears Public Offering | medium |
| Aug 1, 2025 | S-1/A | Heartflow Amends S-1, Nears Public Offering for MedTech Growth | high |
| Jul 17, 2025 | S-1 | Heartflow Files S-1 for IPO, Eyes MedTech Expansion | medium |
Risk Profile
Risk Assessment: Of HTFL's 10 recent filings, 2 were flagged as high-risk, 4 as medium-risk, and 4 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $126.9M |
| Net Income | -$92.4M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $291.2M |
| Operating Margin | N/A |
| Total Assets | $364.4M |
| Total Debt | N/A |
Key Executives
- John C.M. Farquhar
- Shelly Heyduk
- Angela Ahmad
- Dave Peinsipp
- Ryan Coombs
- Kristin VanderPas
- Denny Won
- Charles S. Kim
Industry Context
The medical device industry, particularly in areas like cardiovascular diagnostics, is characterized by rapid innovation, significant R&D investment, and a complex regulatory approval process. Companies often face intense competition and require substantial capital to scale operations and commercialize new technologies.
Top Tags
Medical Devices (5) · IPO (4) · medical-devices (2) · Biotechnology (2) · Net Loss (2) · Revenue Growth (2) · Healthcare Technology (2) · S-1/A (2) · Surgical Instruments (2) · SEC Filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC Accession Number | 0001193125-26-189319 | Unique identifier for the filing |
| Filing Date | 2026-04-29 | Date the document was officially filed with the SEC |
| Revenue | $126.9M | Increased 39.7% for the nine months ended September 30, 2025, from $90.8M in 2024. |
| Net Loss | $92.4M | Widened for the nine months ended September 30, 2025, from $63.5M in 2024. |
| Common Stock Warrant Liability Change | $34.6M | Significant increase in fair value change for the nine months ended September 30, 2025, from $4.5M in 2024. |
| Cash and Cash Equivalents | $291.2M | Increased substantially from $51.4M at December 31, 2024, primarily due to IPO proceeds. |
| IPO Proceeds | $332.3M | Net proceeds from the issuance of common stock upon IPO. |
| Common Shares Outstanding | 83,473,696 | As of September 30, 2025, significantly up from 6,122,048 at December 31, 2024, due to IPO and conversions. |
| Loss on Debt Extinguishment | $6.4M | Incurred during the nine months ended September 30, 2025. |
| Interest Expense | $15.2M | For the nine months ended September 30, 2025, down from $17.6M in 2024. |
| Quarterly Revenue | $43.424M | Increased 40% from $31.054M in Q2 2024 |
| Quarterly Net Loss | $9.196M | Improved from $23.379M in Q2 2024 |
| Six-Month Revenue | $80.629M | Increased 39.3% from $57.897M in H1 2024 |
| Six-Month Net Loss | $41.541M | Improved from $44.311M in H1 2024 |
| Convertible Notes Proceeds | $72.813M | New financing activity in H1 2025 |
Frequently Asked Questions
What are the latest SEC filings for Heartflow, Inc. (HTFL)?
Heartflow, Inc. has 10 recent SEC filings from Jul 2025 to Apr 2026, including 3 8-K, 2 10-Q, 2 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HTFL filings?
Across 10 filings, the sentiment breakdown is: 7 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Heartflow, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Heartflow, Inc. (HTFL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Heartflow, Inc.?
Key financial highlights from Heartflow, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HTFL?
The investment thesis for HTFL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Heartflow, Inc.?
Key executives identified across Heartflow, Inc.'s filings include John C.M. Farquhar, Shelly Heyduk, Angela Ahmad, Dave Peinsipp, Ryan Coombs and 3 others.
What are the main risk factors for Heartflow, Inc. stock?
Of HTFL's 10 assessed filings, 2 were flagged high-risk, 4 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Heartflow, Inc.?
Forward guidance and predictions for Heartflow, Inc. are extracted from SEC filings as they are enriched.